Since the front-line treatment strategy for advanced ovarian cancers is chemotherapy, downregulation of Id-1 may provide a novel strategy in improving the efficiency of chemotherapeutic drugs through suppression of Id-1-induced protection against apoptosis. Here, ID1 is linked to ovarian carcinoma.